December 16, 2020 07:00 ET | Source: PolyPid Ltd.
Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021
PETAH TIKVA, Israel, Dec. 16, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been enrolled and randomized in the SHIELD II (Surgical siteHospital acquiredInfection prEvention withLocalD-plex) trial, the Companys second of two Phase 3 clinical trials for its lead product candidate, D-PLEX100, for the prevention of post-abdominal surgery incisional infection (soft tissue).
Three weeks after D-PLEX100 received Breakthrough Therapy Designation from the FDA, the enrollment of the first patient in our second Phase 3 trial is a significant achievement for our D-PLEX100 clinical development program. Importantly, SHIELD II will have broader eligibility criteria than SHIELD I, with the inclusion of minimally invasive surgical procedures, providing additional clinical evaluation of the potential of D-PLEX100 to prevent surgical site infections (SSIs) in broader target populations, said Amir Weisberg, PolyPids CEO. Enrollment in our first Phase 3 clinical trial, SHIELD I, continues to progress as expected and we anticipate the availability of top-line results from this study in the second half of next year. SHIELD I and SHIELD II will serve as the basis for our first New Drug Application submission.
Based on the compelling data generated to date, D-PLEX100, if approved, has the potential to be a highly effective solution in preventing SSIs, even in the most complex surgical settings such as abdominal surgery with colorectal resection, said Anthony Senagore, M.D., a leading colorectal surgeon, and a medical advisor to PolyPid. As systemic antibiotic penetration into the surgical wound is significantly limited due to blood flow interruption, a substantial unmet need remains in preventing SSIs. I look forward to the continued clinical assessment of this promising therapeutic candidate in the SHIELD I and SHIELD II studies.
SHIELD II (NCT04411199) is a prospective, multinational, multicenter, randomized, double-blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the Standard of Care (SoC), compared to a SoC-treated control arm, for the prevention of post-abdominal surgery incisional infection.The primary endpoint of the trial is the infection rate, as measured by the proportion of subjects with at least one abdominal target incisional infection event within 30 days post-abdominal surgery, determined by a blinded independent adjudication committee.The trial will enroll a minimum of 900 patients, with a maximum of approximately 1,400 subjects, as defined by the adaptive study design, in approximately 60 centers in the United States, Europe and Israel.
AboutD-PLEX100
PolyPids lead product candidate, D-PLEX100, is a novel drug product candidate designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX technology enables a prolonged and constant release of the broad-spectrum antibiotic doxycycline, resulting in high local concentration of the drug for a period of four weeks for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX100 has also received two Qualified Infectious Disease Product (QIDP) designations as well as two Fast Track designations for the prevention of post-abdominal surgery incisional infection and for the prevention of sternal wound infection post-cardiac surgery.
AboutPolyPid
PolyPidis a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. PolyPids product candidates are designed to address diseases with high unmet medical needs by pairing PLEX with drugs to deliver them directly to precise sites in the body at predetermined release rates and over durations ranging from several days to several months. PolyPids lead product candidate, D-PLEX100, is in Phase 3 clinical trials for the prevention of sternal SSIs and abdominal SSIs. PolyPids technology and products are based on the inventions and the professional leadership of Dr.Noam Emanuel, the Founder and the Chief Scientific Officer of the company.
For additional company information, visitwww.polypid.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements. For example, PolyPid is using forward-looking statements in this press release when it discusses the potential of D-PLEX100 to prevent SSIs, and the enrollment and timing of clinical trials. Because such statements deal with future events and are based on PolyPids current expectations, they are subject to various risks and uncertainties. Also, while PolyPid has received Fast Track Designation for D-PLEX100 for the prevention of SSIs, it cannot guarantee that it will be able to maintain such designation due to reasons within our outside of its control. Actual results, performance or achievements of PolyPid could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading Risk Factors in PolyPids final prospectus dated June 25, 2020, filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission (SEC), and in any subsequent filings with the SEC. Except as otherwise required by law, PolyPid undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
- Home - MedStar Heart & Vascular Institute - April 16th, 2018 [April 16th, 2018]
- Guidelines for Standards in Cardiac Surgery - April 16th, 2018 [April 16th, 2018]
- Cardiac Surgery - University of Ottawa Heart Institute - June 16th, 2018 [June 16th, 2018]
- Cardiac Surgery | UNC Medical Center, Hospitals Chapel ... - June 18th, 2018 [June 18th, 2018]
- Heart Surgery | Seattle Childrens Hospital - June 18th, 2018 [June 18th, 2018]
- Pediatric Cardiac Surgery | CHKD | Norfolk, VA - June 18th, 2018 [June 18th, 2018]
- Cardiac Surgery | McLaren Port Huron - July 4th, 2018 [July 4th, 2018]
- CardioVascular Thoracic Institute (CVTI) | The most ... - July 23rd, 2018 [July 23rd, 2018]
- Top Cardiac Surgery COST in India| Benefit - IndianHealthGuru - July 27th, 2018 [July 27th, 2018]
- Cardiac Surgery - Atrial Septal Defect - August 6th, 2018 [August 6th, 2018]
- Cardiac Surgery | Stony Brook Medicine - August 6th, 2018 [August 6th, 2018]
- Cardiac Surgery in the Adult Fifth Edition: Lawrence H. Cohn ... - August 6th, 2018 [August 6th, 2018]
- Pioneers of Cardiac Surgery: 9780826515940: Medicine & Health ... - August 6th, 2018 [August 6th, 2018]
- Cardiovascular Surgery Department | Cleveland Clinic - August 6th, 2018 [August 6th, 2018]
- Cardiac Surgery - Massachusetts General Hospital, Boston, MA - September 19th, 2018 [September 19th, 2018]
- Cardiac Surgery | Surgery | UC Cincinnati College of ... - September 25th, 2018 [September 25th, 2018]
- Cardiothoracic surgery - Wikipedia - September 25th, 2018 [September 25th, 2018]
- Cardiac Surgery | NorthShore - September 25th, 2018 [September 25th, 2018]
- Open Heart Surgery - Cardiac Surgery - University of ... - September 25th, 2018 [September 25th, 2018]
- Heart Surgery | Cleveland Clinic - September 25th, 2018 [September 25th, 2018]
- Cardiac Surgery - Ventricular Assist Devices (VAD) - October 4th, 2018 [October 4th, 2018]
- VCSQI | Virginia Cardiac Services Quality Initiative ... - October 12th, 2018 [October 12th, 2018]
- Cardiac Surgery | Boston Medical Center - October 15th, 2018 [October 15th, 2018]
- Cardiac Surgery | WVU Heart and Vascular Institute - November 10th, 2018 [November 10th, 2018]
- Cardiac Surgery - Heart Valve, Bypass | GW Hospital - November 13th, 2018 [November 13th, 2018]
- Cardiac Surgery - Department of Surgery - University of ... - November 29th, 2018 [November 29th, 2018]
- Cardiac Surgery - Jersey Shore University Medical Center - December 7th, 2018 [December 7th, 2018]
- Blunt Cardiac Injury - The American Association for the ... - December 20th, 2018 [December 20th, 2018]
- Minimally invasive cardiac surgery - Wikipedia - December 20th, 2018 [December 20th, 2018]
- Heart Surgery | Private cardiac specialists in London ... - December 20th, 2018 [December 20th, 2018]
- Cardiac Surgery - Waterbury Hospital - December 20th, 2018 [December 20th, 2018]
- Cardiac surgery - Wikipedia - December 25th, 2018 [December 25th, 2018]
- Heart Surgery | Memorial Healthcare System - December 31st, 2018 [December 31st, 2018]
- A Step-By-Step Look at Open Heart Bypass Surgery - December 31st, 2018 [December 31st, 2018]
- Cardiac Surgery - Erlanger - December 31st, 2018 [December 31st, 2018]
- Inova Cardiac and Thoracic Surgery | Northern VA & DC - Inova - March 6th, 2019 [March 6th, 2019]
- Cardiac Surgery | Heart and Vascular Center | Dartmouth ... - March 13th, 2019 [March 13th, 2019]
- Cardiovascular Medicine and Cardiac Surgery - April 1st, 2019 [April 1st, 2019]
- Minimally invasive heart surgery - Mayo Clinic - April 3rd, 2019 [April 3rd, 2019]
- Home > Cardiac Surgery | Surgery | Yale School of Medicine - April 16th, 2019 [April 16th, 2019]
- Heart and Vascular Care Services - UR Medicine, University ... - April 18th, 2019 [April 18th, 2019]
- Welcome! | LHSC - April 20th, 2019 [April 20th, 2019]
- Cardiac Surgery | Department of Surgery | The University ... - April 20th, 2019 [April 20th, 2019]
- Coronary bypass surgery - Mayo Clinic - April 23rd, 2019 [April 23rd, 2019]
- Cardiovascular Surgery - Overview - Mayo Clinic - April 23rd, 2019 [April 23rd, 2019]
- Cardiac Surgery | McLaren Health Care - April 23rd, 2019 [April 23rd, 2019]
- Volunteer opens heart to his faith after healing cardiac ... - April 23rd, 2019 [April 23rd, 2019]
- Heart Surgery - UChicago Medicine - April 27th, 2019 [April 27th, 2019]
- Heart Surgery | UM St. Joseph Medical Center - May 13th, 2019 [May 13th, 2019]
- Cardiac Surgery - Billings Clinic - May 13th, 2019 [May 13th, 2019]
- Cardiology and Cardiac Surgery - Chicago Cardiologists and ... - May 23rd, 2019 [May 23rd, 2019]
- Cardiac Surgery | Michigan Medicine | University of Michigan - September 11th, 2019 [September 11th, 2019]
- Guidelines for Perioperative Care in Cardiac Surgery ... - September 11th, 2019 [September 11th, 2019]
- Cannula Market To Flourish And Reach USD 433 Million By 2025 - ZMR News Network - October 4th, 2019 [October 4th, 2019]
- Heart Health: Dr Panda says one should never give up on a patient - Republic World - October 4th, 2019 [October 4th, 2019]
- Minimally Invasive Surgery Market 2024 By Manufacturers, Investment Feasibility, Cost Structure And Swot Analysis - The Washington Observer - October 4th, 2019 [October 4th, 2019]
- Michael Schumacher health latest: What is stem cell therapy and how will it help Schumi? - Express.co.uk - October 4th, 2019 [October 4th, 2019]
- Cooperative insurance: Novel financing model aims to deliver healthcare to the middle-class segment - The Hindu BusinessLine - October 4th, 2019 [October 4th, 2019]
- Optimism Linked to Lower Risk of Cardiovascular Events and Death - Cath Lab Digest - October 4th, 2019 [October 4th, 2019]
- Global Cardiac Surgery Devices Market 2019 Innovative Trends and Insights Research upto 2024 - Markets Gazette - October 4th, 2019 [October 4th, 2019]
- Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist - Diagnostic and Interventional Cardiology - October 4th, 2019 [October 4th, 2019]
- Economics of Cochlear Implant Utilization : The Hearing Journal - LWW Journals - October 4th, 2019 [October 4th, 2019]
- How to Keep the Weight Off After Bariatric Surgery - Health Essentials from Cleveland Clinic - October 4th, 2019 [October 4th, 2019]
- Heart Lung Machine Market to Upsurge at 6.13% CAGR by 2023, Owing to Increasing Demand From the Healthcare Sector: Radiant Insights, Inc. - PRNewswire - October 4th, 2019 [October 4th, 2019]
- Annadale toddler born with rare condition is fighting for her life - SILive.com - October 4th, 2019 [October 4th, 2019]
- Ocala Health earns distinction, ranks among top within HCA open heart programs - Ocala News - October 4th, 2019 [October 4th, 2019]
- External Validation Of The Surgical Mortality Probability Model (S-MPM | TCRM - Dove Medical Press - October 4th, 2019 [October 4th, 2019]
- CytoSorb Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac... - October 4th, 2019 [October 4th, 2019]
- Transcatheter Tricuspid Fix Bests Meds Alone in Early Results - Medscape - October 15th, 2019 [October 15th, 2019]
- Senior Lecturer/Associate Professor in Medical Statistics job with UNIVERSITY OF BRISTOL | 183393 - Times Higher Education (THE) - October 15th, 2019 [October 15th, 2019]
- Complicated surgery at NICVD saves life of nine-year-old boy - The News International - October 15th, 2019 [October 15th, 2019]
- Angion Announces Several Strategic Additions to its Management Team to Support the Future Development and Commercialization of ANG-3777 - Yahoo... - October 15th, 2019 [October 15th, 2019]
- 'Sky is the limit' for heart treatment without invasive surgery - Ottawa Citizen - October 15th, 2019 [October 15th, 2019]
- Executive Profile: Dr. David Anschel - Long Island Business News - October 15th, 2019 [October 15th, 2019]
- Heart surgeon and author reveals how he once set fire to patient - The Guardian - October 15th, 2019 [October 15th, 2019]
- Demolition paves way for heart, vascular center - Midland Daily News - October 15th, 2019 [October 15th, 2019]
- The basics of research | TNS - The News on Sunday - October 15th, 2019 [October 15th, 2019]
- Senior Lecturer/Associate Professor in Medical Statistics job with UNIVERSITY OF BRISTOL | 183345 - Times Higher Education (THE) - October 15th, 2019 [October 15th, 2019]
- Sparks, Accusations Fly Over Conduct of EXCEL Trial - Medscape - October 15th, 2019 [October 15th, 2019]
- More Heart Valve Patients May Choose Minimally Invasive Procedure - Newswise - October 15th, 2019 [October 15th, 2019]